NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/zynex-inc-lawsuit-submissio ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form? ...

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=146161&from=4 CLASS PERIOD: March 13, 2023 to March 11, 2025 ...

Financial Data and Key Metrics Changes - Net revenue for Q1 2025 was $26.6 million, a decrease from $46.5 million in Q1 2024, primarily due to a temporary payment suspension from TRICARE and slowing order growth [20][21] - Gross profit in Q1 2025 was $18.2 million, representing 69% of revenue, compared to $37.2 million or 80% of revenue in Q1 2024 [20][21] - Net loss for Q1 2025 was $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the previous year [21][22] Business Line Data and Key Metrics Changes - Device revenue was $11.9 million, while supplies revenue was $14.7 million in Q1 2025 [20] - Non-NexWave product order percentage increased to 34% in Q1 2025, up from an average of 30% in the previous year [13] Market Data and Key Metrics Changes - The company is experiencing a temporary payment suspension from TRICARE, which has affected revenue recognition [6][12] - The patient monitoring market is identified as a multibillion-dollar opportunity, with the company planning to enter with a superior product [19] Company Strategy and Development Direction - The company is restructuring to operate without TRICARE business in a worst-case scenario and is focusing on new revenue opportunities [9][10] - The company aims to generate revenue exceeding $800 million annually in the long term [25] - The launch of the Nico pulse oximeter is anticipated to significantly impact the patient monitoring market, with a focus on improving health equity [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth prospects despite current challenges, emphasizing a commitment to high-quality service and technology [24][25] - The company expects to receive a response from TRICARE regarding the payment suspension within 40 days [24] Other Important Information - The company has reduced overall staff by approximately 15%, primarily in the corporate office, which is expected to result in annual savings of about $35 million [13] - The company maintains a strong balance sheet with $40 million in working capital and approximately $24 million in cash [22] Q&A Session Summary Question: Insights into TRICARE conversations and potential domino effects - Management indicated that the claims from TRICARE were vague and emphasized compliance with guidelines, stating there are no current issues with other payers [28][30][31] Question: Clarification on Q1 revenue miss and future guidance - The revenue miss was attributed to multiple factors, and management is waiting for clarity on TRICARE before providing full-year guidance [32][34][35] Question: Confirmation of TRICARE payments in Q1 and Q2 guidance - Management confirmed that Q1 revenue and guidance for Q2 do not include TRICARE payments, and they expect reimbursement for claims once the suspension is lifted [37][38] Question: Plans if TRICARE outcome is negative - The company plans to refocus its sales force to generate revenue from other areas if TRICARE payments are not restored [40][41] Question: Expected revenue from Nico post-approval - Management expects to launch Nico immediately upon FDA clearance, with revenue anticipated in 2026 [42]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors of a class action representing investors that bought securities between March 13, 2023 and March 11, 2025, inclusive (the "Class Period"). Zynex investors have until May 19, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by ph ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities between March 13, 2023, and March 11, 2025, of the May 19, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Zynex securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by May 19, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, which inflated its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, leading to potential adverse consequences [4] - The lawsuit asserts that the defendants' positive statements about Zynex's business were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [4]

Zynex (ZYXI) Q1 2025 Earnings Call April 29, 2025 04:15 PM ET Company Participants Brian Prenoveau - Investor RelationsThomas Sandgaard - Chairman, President and CEOAnna Lucsok - Chief Operating OfficerDonald Gregg - President of Zynex Monitoring SolutionsDan Moorhead - Chief Financial OfficerYi Chen - Managing Director, Equity Research Conference Call Participants Shagun Singh - Medical Technology Analyst Operator Afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter twenty twenty five Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) | NEVADA | 90-0275169 | | --- | --- ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Exhibit 99.1 Zynex Reports First Quarter 2025 Financial Results ENGLEWOOD, Colo., April 29, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management a ...